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Abstract. A 35-year-old man with a 19-year history of slowly evolving diffuse cutaneous leishmaniasis was treated
with oral miltefosine, 50 mg three times a day. The patient responded after four months of miltefosine treatment with
clearance of all nodular lesions and plaques from the entire body surface and had negative slit-skin smears and cultures
for Leishmania. However, two months after stopping miltefosine, skin lesions reappeared and parasites were observed
in samples. The relapsed lesions did not respond to an additional two-month course of miltefosine. No laboratory or
clinical adverse events to miltefosine were observed. Parasites from skin lesions were cultured and identified as Leish-
mania (Leishmania) mexicana by isoenzyme electrophoresis.
INTRODUCTION
Current chemotherapy for leishmaniasis has never been so
promising with the introduction of new drugs and formula-
tions such as miltefosine and liposomal amphotericin B. How-
ever, the usefulness of these new compounds for the treat-
ment of the rare clinical presentation of diffuse cutaneous
leishmaniasis (DCL) is uncertain. New World DCL (NW-
DCL) is a serious illness caused by parasites of the Leishma-
nia subgenus in patients with poor cell-mediated immunity
(anergic) to Leishmania parasites. Results of the skin test
reaction to Leishmania antigens (LST) in these patients are
negative. NW-DCL has been reported in several countries in
Central and South America, and is characterized by widely
disseminated non-ulcerating skin papules, nodules, and
plaques.1
DCL never heals spontaneously and is highly resistant to
chemotherapy. Currently, there is no effective treatment for
NW-DCL and treatment with antimonial drugs or other drugs
produces only transitory remissions.2–6 Data are limited on
the clinical efficacy of oral miltefosine (hexadecylphospho-
choline) for the treatment on NW-DCL. However, it has been
shown to be highly effective for the treatment of visceral
leishmaniasis7 and some of the New World cutaneous leish-
maniasis,8 and has shown efficacy in immunocompromised
patients co-infected with human immunodeficiency virus.9 In
a study in Venezuela, 10 of 12 patients with NW-DCL treated
with 2.0–2.5 mg/kg/day of miltefosine were Leishmania nega-
tive after 2.5 months of treatment, but the outcome of treat-
ment was not reported after withdrawal of miltefosine (Zerpa
O and others, unpublished data). We describe a patient with
DCL associated with L. (Leishmania) mexicana infection
from Ecuador whose disease resolved completely clinically
and parasitologically after four months of oral miltefosine
(2.5 mg/kg/day) but relapsed two months after stopping
this treatment and failed to respond to a second course of
miltefosine.
CASE REPORT
A 35-year-old Ecuadorian man in March 2005 had violet-
brown non-ulcerated papules, nodules, and plaques distrib-
uted diffusely on the skin of his face, trunk, arms, and legs. A
medical history showed that the lesions appeared when he
was 16 years of age and were initially diagnosed as leprosy for
which he received treatment. He was seen for the first time by
our research team (E.A.G. and Y.H.) in August 1988 and had
positive slit-skin smears and cultures for Leishmania. DCL
was diagnosed after histologic examination of skin biopsy
specimens and a negative LST result.10 The patient was
treated with meglumine antimoniate (Glucantime) and so-
dium stibogluconate (Pentostam) at doses of 20 mg of Sb/kg/
day for 28 days with each drug; partial resolution of skin
lesions was observed but relapsed soon after withdrawal of
treatment. He received also pentamidine but this was discon-
tinued because of severe adverse reactions. Subsequently, he
was treated with oral mefloquine, artesunate, and itracona-
zole.
By March 2005, the patient had the disease for 19 years and
had been treated with different drugs, but the lesions contin-
ued to progress (Figure 1). The patient requested an alterna-
tive treatment. Oral miltefosine was given under a compas-
sionate use program of the manufacturer (Zentaris GmbH,
Frankfurt, Germany). After detailed clinical, laboratory, and
histopathologic evaluation and a negative LST result, milte-
fosine (Impavido) was given at a dose of 2.5 mg/kg/day. The
parasites isolated were identified as L. (L.) mexicana by mul-
tilocus enzyme electrophoresis by comparing electrophoretic
profiles of 11 isoenzymes with those of World Health Orga-
nization reference strains. He was evaluated every two weeks
during treatment to ensure treatment compliance, detect any
miltefosine-related adverse reactions, and evaluate the re-
sponse to miltefosine. In addition, he underwent monthly
laboratory examinations including routine evaluations of
blood, urine, and liver function and microscopic examination
of scrapings and culture of lesion aspirates. Six weeks after
treatment with miltefosine had started, the skin lesions had
decreased in size, but smears remained positive for Leishma-
nia. After four months of treatment, all lesions had cleared
(Figure 2) and slit-skin smears and cultures were negative.
Miltefosine was given for an additional month (total of five
months of treatment) and the skin lesions remained cured
with apparent parasitologic sterility. Clinically significant al-
terations in routine blood and urine examinations and ad-
verse reactions to treatment were not observed.
Unfortunately, two months after discontinuing miltefosine
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(seven months after the start of treatment), small papular
lesions appeared (Figure 3) and the slit-skin smears and as-
pirates of lesions were positive for Leishmania parasites.
Miltefosine was again given at same dose, but no clinical or
parasitologic response was observed after two months of re-
treatment, and skin lesions continued to grow and dissemi-
nate over his entire body.
DISCUSSION
New World DCL has been reported in the United States,
Mexico, Dominican Republic, Honduras, Venezuela, Colom-
bia, French Guyana, Brazil, Peru, Paraguay, and Bolivia.1,11
The Leishmania species most commonly associated with DCL
in the New World is L. (L.) amazonensis,1 although cases
associated with L. (L.) mexicana and L. (V.) panamensis in-
fection have been reported in Mexico and Colombia.12,13
A single, standard, high-dose course of pentavalent anti-
monial drugs is the recommended chemotherapy for the leish-
maniases in the New World.14 However, with the exception of
an anecdotal case in Colombia,13 no patient with DCL has
been cured with this treatment regimen even after adminis-
tration of several courses of treatment, as demonstrated in the
present case who had received approximately 480 ampules of
antimony by the time of the initiation of treatment with milte-
fosine. Numerous other options have been evaluated for the
treatment of NW-DCL, including local heat treatment,3
gamma-interferon in combination with pentamidine and allo-
purinol,2 or pentavalent antimony.6 Immunotherapy using
Leishmania antigens plus bacillus Calmette-Guérin or in com-
bination with antimoniate meglumine appeared to be useful
in Venezuelan patients with early lesions of DCL,4 but only
produced clinical improvement in patients with chronic infec-
tion.5 In the present case, we used the alternative drug pent-
amidine, but this was discontinued because of adverse
reactions. Mefloquine and artemisinin, which have been re-
ported to be effective for the treatment of localized cutaneous
leishmaniasis (CL) in Ecuador,15 were used also in this case
with partial improvement in skin lesions, but there was no
clinical response to itraconazole.
The efficacy of miltefosine has not been reported widely for
NW-DCL, although a preliminary study provided evidence
FIGURE 2. The back of the patient four months after the start of
miltefosine treatment. The skin is cleared of lesions that left perma-
nent depressed scars. Smears and cultures were negative for Leish-
mania parasites.
FIGURE 3. The back of the patient two months after stopping
miltefosine treatment. Multiple, small, and painless papules have de-
veloped in the whole body around the old lesion scars. Numerous
parasites were observed microscopically in slit-skin smears and cul-
tures taken from the new lesions.
FIGURE 1. Widespread dissemination of papules, nodules, and
plaques lesions on the back of the patient before starting miltefosine
treatment. The leishmanin skin test result was negative and parasites
were identified as Leishmania (Leishmania) mexicana. Infection did
not affect the skin of palms, soles, or scrotum.
MILTEFOSINE AND DIFFUSE CUTANEOUS LEISHMANIASIS 1075
for clinical and parasitologic cure in 10 of 12 Venezuelan
cases (Zerpa O and others, unpublished data). In the present
trial, however, similar daily doses (2.5 mg/kg/day) adminis-
tered for a longer period (five months) failed to cause clinical
cure and complete relapse was observed two-months post-
treatment. The apparent success of the Venezuelan study was
not clear because follow-up data on clinical status of the sub-
jects were not provided beyond the completion of therapy.
However, most of the patients in this study relapsed after
several months of apparent remission (Sindermann H, unpub-
lished data). In the study of Zerpa and others, speciation of
the parasites was not performed, and the investigators pre-
sumed that the parasite were L. mexicana complex. In our
case, parasites were identified as L. (L.) mexicana. Differ-
ences in the therapeutic response to miltefosine between spe-
cies of New World Leishmania have been reported in vitro
and in a clinical trial.8,16 An L. (L.) mexicana isolate from
Peru was not sensitive to miltefosine in a macrophage-
amastigote model,16 and clinical cases of CL in Guatemala
where L. (L.) mexicana and L. (V.) braziliensis are common
were less responsive than Colombian cases.8
In our subject, an early and full clinical response to milte-
fosine was observed, but a relapse was noted after several
months. Such a promising initial clinical response but a failure
to respond after the start of a second course of miltefosine
could be explained by the acquisition of resistance by the
parasites. Observations from India suggest that relapsing
cases are resistant to miltefosine.17 In addition, laboratory
studies have predicted that multidrug resistance could affect
sensitivity to miltefosine and its analogs.14 Resistant promas-
tigotes of L. donovani, the most sensitive species to miltefos-
ine, have been generated in vitro and caused by reduced ac-
cumulation of 14C-labeled miltefosine. Point mutations in the
membrane P-type transporter (LDMT gene) that is respon-
sible for the uptake of miltefosine and glycerophospholipids
have been identified that cause reduced uptake of miltefosine
into promastigotes. Another species of Leishmania (L.[ L.]
tropica) that overexpresses a P-glycoprotein is less sensitive to
miltefosine.
Although the therapeutic activity of miltefosine is consid-
ered to be a consequence of direct effects of the drug on
Leishmania parasites18 that are independent of host immu-
nity, the relapse of DCL in our patient after a five-month
course of high-dose miltefosine may indicate that host immu-
nity has an important role in preventing relapse.
In conclusion, although miltefosine induced an early clini-
cal response in our patient with NW-DCL, in agreement with
a previous study in Venezuela, the high risk of relapse in-
dicates a need for investigating new drug combinations or
maintenance regimens. Because cell-mediated immunity
against Leishmania parasites is poor or absent in patients with
DCL, combination treatments of miltefosine with agents that
increase host immune responses such as immunotherapy
should be considered.
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